1.Osteomyelitis: A Descriptive Study.
Laura PRIETO-PEREZ ; Ramon PEREZ-TANOIRA ; Elizabet PETKOVA-SAIZ ; Concepcion PEREZ-JORGE ; Cristina LOPEZ-RODRIGUEZ ; Beatriz ALVAREZ-ALVAREZ ; Jorge POLO-SABAU ; Jaime ESTEBAN
Clinics in Orthopedic Surgery 2014;6(1):20-25
BACKGROUND: To analyze the incidence and clinical-microbiological characteristics of osteomyelitis (OM) in a tertiary Spanish hospital. METHODS: All cases diagnosed with OM between January 2007 and December 2010 were retrospectively reviewed. The variables examined include epidemiological characteristics, risk factors, affected bone, radiographic changes, histology, microbiological culture results, antibiotic treatment, and the need for surgery. RESULTS: Sixty-three cases of OM were diagnosed. Twenty-six patients (41.3%) had acute OM whereas 37 patients (58.7%) were classified as chronic OM. OM may result from haematogenous or contiguous microbial seeding. In this group, 49 patients (77.8%) presented with OM secondary to a contiguous source of infection and 14 patients had hematogenous OM (22.2%). Staphylococcus aureus was the most commonly found microorganism. CONCLUSIONS: OM mainly affected patients with risk factors related to the presence of vascular diseases. Antibiotic treatment must be guided by susceptibility patterns of individual microorganisms, although it must be performed together with surgery in most of the cases.
Acute Disease
;
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Bacterial Agents/therapeutic use
;
Child
;
Child, Preschool
;
Chronic Disease
;
Female
;
Humans
;
Infant
;
Male
;
Middle Aged
;
*Osteomyelitis/drug therapy/epidemiology/microbiology
;
Retrospective Studies
;
Risk Factors
;
Spain/epidemiology
;
Staphylococcal Infections
;
Staphylococcus aureus/isolation & purification
;
Tertiary Care Centers
;
Young Adult
2.Association between angiotensin-1 converting enzyme gene olymorphism and the metabolic syndrome in a Mexican opulation.
Cleto ALVAREZ-AGUILAR ; Maria Lucia ENRIQUEZ-RAMIREZ ; Benigno FIGUEROA-NUNEZ ; Anel GOMEZ-GARCIA ; Ernesto RODRIGUEZ-AYALA ; Cristina MORAN-MOGUEL ; Victor Manuel FARIAS-RODRIGUEZ ; Dolores MINO-LEON ; Joel Edmundo LOPEZ-MEZA
Experimental & Molecular Medicine 2007;39(3):327-334
Metabolic Syndrome (MS) is recognized as a cluster of cardiovascular risk factors. All components of MS have a genetic base. Genes of the renin angiotensin system are potential candidate genes for MS. We investigated whether angiotensin converting enzyme (ACE) gene polymorphism increases susceptibility to MS as an entity in a Mexican population. In a cross-sectional study, 514 individuals were studied including 245 patients with MS and 269 subjects without MS criteria. ACE gene polymorphism was detected using PCR. MS was defined according to The National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) criteria, except that the raised fasting plasma glucose >or=100 mg/dl criterion for identification of intolerance fasting glucose was modified in accordance with the suggestion of the American Diabetes Association. Patients with MS were significantly different from subjects without MS in relation to mean body mass index (BMI), waist circumference (WC), systolic blood pressure, diastolic blood pressure, glucose, total cholesterol (C), triglycerides, HDL-C, and LDL-C (P<0.0001). The differences in the mean BMI, WC, glucose, total cholesterol, triglycerides, LDL-C, and HDL-C were maintained in patients with the MS and DD genotypes (P<0.01). The DD genotype was strongly associated with MS (adjusted OR=5.48, 95% CI 3.20-9.38, P<0.0001). We concluded that the DD genotype increases susceptibility to MS in a Mexican population. These results indicate that pharmacological and non-pharmacological treatment and a reduction in body fat will have important therapeutic implications in this disease.
Aged
;
Cross-Sectional Studies
;
Female
;
*Genetic Predisposition to Disease
;
Humans
;
Male
;
Metabolic Syndrome X/*genetics
;
Mexico
;
Middle Aged
;
Peptidyl-Dipeptidase A/*genetics
;
*Polymorphism, Genetic
;
Population Groups/genetics
;
Risk Factors